Monte Rosa Therapeutics Inc., a clinical-stage biotechnology company focused on developing novel molecular glue degrader-based medicines, will participate in the upcoming Stifel 2025 Virtual Immunology and Inflammation Forum. Markus Warmuth, M.D., the Chief Executive Officer, will engage in a fireside chat on September 15, 2025, at 9:00 a.m. ET.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Monte Rosa Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9521319-en) on September 02, 2025, and is solely responsible for the information contained therein.